Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

353 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Intravenous immunoglobulin for Guillain-Barré syndrome.
Hughes RA, Swan AV, van Doorn PA. Hughes RA, et al. Among authors: van doorn pa. Cochrane Database Syst Rev. 2012 Jul 11;(7):CD002063. doi: 10.1002/14651858.CD002063.pub5. Cochrane Database Syst Rev. 2012. PMID: 22786476 Updated. Review.
Treatment of immune neuropathies.
Van Doorn PA, Garssen MP. Van Doorn PA, et al. Curr Opin Neurol. 2002 Oct;15(5):623-31. doi: 10.1097/00019052-200210000-00014. Curr Opin Neurol. 2002. PMID: 12352007 Review.
Anti-GM1 IgG antibodies induce leukocyte effector functions via Fcgamma receptors.
van Sorge NM, van den Berg LH, Geleijns K, van Strijp JA, Jacobs BC, van Doorn PA, Wokke JH, van de Winkel JG, Leusen JH, van der Pol WL. van Sorge NM, et al. Among authors: van den berg lh, van strijp ja, van doorn pa, van de winkel jg, van der pol wl. Ann Neurol. 2003 May;53(5):570-9. doi: 10.1002/ana.10503. Ann Neurol. 2003. PMID: 12730990
Immunotherapy for Guillain-Barré syndrome.
van Doorn PA, van Koningsveld R. van Doorn PA, et al. Among authors: van koningsveld r. Lancet Neurol. 2004 Feb;3(2):84. doi: 10.1016/s1474-4422(03)00660-4. Lancet Neurol. 2004. PMID: 14746999 Review. No abstract available.
Functional polymorphisms in LPS receptors CD14 and TLR4 are not associated with disease susceptibility or Campylobacter jejuni infection in Guillain-Barré patients.
Geleijns K, Jacobs BC, Van Rijs W, Tio-Gillen AP, Laman JD, van Doorn PA. Geleijns K, et al. Among authors: van rijs w, van doorn pa. J Neuroimmunol. 2004 May;150(1-2):132-8. doi: 10.1016/j.jneuroim.2004.01.003. J Neuroimmunol. 2004. PMID: 15081257
Treatment of chronic inflammatory demyelinating polyneuropathy.
van Doorn PA, Ruts L. van Doorn PA, et al. Curr Opin Neurol. 2004 Oct;17(5):607-13. doi: 10.1097/00019052-200410000-00011. Curr Opin Neurol. 2004. PMID: 15367865 Review.
Fas polymorphisms are associated with the presence of anti-ganglioside antibodies in Guillain-Barre syndrome.
Geleijns K, Laman JD, van Rijs W, Tio-Gillen AP, Hintzen RQ, van Doorn PA, Jacobs BC. Geleijns K, et al. Among authors: van rijs w, van doorn pa. J Neuroimmunol. 2005 Apr;161(1-2):183-9. doi: 10.1016/j.jneuroim.2004.12.001. J Neuroimmunol. 2005. PMID: 15748958
Severity of Guillain-Barré syndrome is associated with Fc gamma Receptor III polymorphisms.
van Sorge NM, van der Pol WL, Jansen MD, Geleijns KP, Kalmijn S, Hughes RA, Rees JH, Pritchard J, Vedeler CA, Myhr KM, Shaw C, van Schaik IN, Wokke JH, van Doorn PA, Jacobs BC, van de Winkel JG, van den Berg LH. van Sorge NM, et al. Among authors: van der pol wl, van schaik in, van doorn pa, van de winkel jg, van den berg lh. J Neuroimmunol. 2005 May;162(1-2):157-64. doi: 10.1016/j.jneuroim.2005.01.016. J Neuroimmunol. 2005. PMID: 15833371
Treatment of Guillain-Barré syndrome and CIDP.
van Doorn PA. van Doorn PA. J Peripher Nerv Syst. 2005 Jun;10(2):113-27. doi: 10.1111/j.1085-9489.2005.0010203.x. J Peripher Nerv Syst. 2005. PMID: 15958124 Review.
Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuations.
Ruts L, van Koningsveld R, van Doorn PA. Ruts L, et al. Among authors: van koningsveld r, van doorn pa. Neurology. 2005 Jul 12;65(1):138-40. doi: 10.1212/01.wnl.0000167549.09664.b8. Neurology. 2005. PMID: 16009902
353 results
Jump to page
Feedback